Lonza Group Ltd booked an IFRS profit from continuing operations of CHF 909 million for the year ended Dec 31 2025, up 51% year-on-year, as higher volumes and improved mix in its Contract Development and Manufacturing Organisation (CDMO) activities underpinned earnings.

Group sales from continuing operations rose 19.2% year-on-year to CHF 6.53 billion. Core earnings per share (EPS) increased 15% to CHF 15.08 from CHF 13.12 a year earlier. The company did not declare any dividend in the results materials.

Segment performance showed broad-based growth, led by Integrated Biologics, where revenue climbed 26.6% to CHF 3.65 billion and core EBITDA increased 23.2% to CHF 1.29 billion for a 35.3% margin. Advanced Synthesis posted a 21.8% rise in sales to CHF 1.61 billion, while core EBITDA surged 39.3% to CHF 674 million, lifting the margin to 41.2%. Specialized Modalities remained under pressure; revenue fell 5.9% to CHF 1.03 billion and core EBITDA slipped 8.3% to CHF 176 million, reflecting softer demand in certain modalities. Corporate activities, including currency hedging, recorded a negative core EBITDA of CHF 73 million.

Reported profitability was also supported by lower restructuring and divestiture charges versus the prior year, although one-off environmental and impairment expenses continued to weigh on statutory earnings. The net debt/CORE EBITDA ratio improved to 1.4 times from 1.5 times, aided by higher operating cash flow of CHF 674 million before acquisitions.

During the period, Lonza completed its “One Lonza” simplification, reorganising into three CDMO business platforms—Integrated Biologics, Advanced Synthesis and Specialized Modalities—and formally treated Capsules & Health Ingredients as discontinued operations. Capital expenditure totalled CHF 1.37 billion, focused on expanding biologics capacity and integrating the Vacaville site acquired in 2024.

Looking ahead, management reiterated ongoing investments in biologics manufacturing, digital transformation under the Nexus ERP rollout and further optimisation of the manufacturing network, but provided no quantitative earnings guidance in the report.